Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway
Biao Zheng, Guojun Yao, Yuli Pang, Jielong Luo, Zhiyong Yang, Fengmin Xiu, Chaohui Zhen, Rui Liang · 2026
Read Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway by Biao Zheng, Guojun Yao, Yuli Pang, Jielong Luo, Zhiyong Yang, Fengmin Xiu, Chaohui Zhen, Rui Liang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13287138.txt.
Description
Biao Zheng and colleagues test tetrandrine, a plant-derived compound, as a partner for anti-PD-1 immunotherapy in liver cancer. Their 2026 study combines cell experiments, including killer T cells grown with tumor cells, with two mouse models of the disease. The compound was already known to slow tumor growth, yet its pairing with checkpoint therapy was untested.
Tetrandrine damaged tumor DNA, leaving loose DNA fragments that switched on the STING alarm pathway and its downstream signals. T cells in treated cultures activated, multiplied, and released more attack molecules. Silencing STING erased the benefit, proving the pathway's central role. In mice, the combination shrank tumors far better than either agent alone, drew in more killer T cells, and showed no obvious toxicity.
Catalog record
| CREATOR | Biao Zheng, Guojun Yao, Yuli Pang, Jielong Luo, Zhiyong Yang, Fengmin Xiu, Chaohui Zhen, Rui Liang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |